90568
Fenofibric acid
analytical standard
Synonym(s):
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic acid, Fenofibric acid
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C17H15ClO4
CAS Number:
Molecular Weight:
318.75
UNSPSC Code:
77101502
NACRES:
NA.24
PubChem Substance ID:
EC Number:
255-626-9
Beilstein/REAXYS Number:
2058973
MDL number:
grade
analytical standard
Quality Segment
assay
≥98.0% (HPLC)
shelf life
limited shelf life, expiry date on the label
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
impurities
≤1.0% water
application(s)
forensics and toxicology
pharmaceutical (small molecule)
format
neat
SMILES string
O=C(C1=CC=C(OC(C)(C)C(O)=O)C=C1)C2=CC=C(Cl)C=C2
InChI
1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)
InChI key
MQOBSOSZFYZQOK-UHFFFAOYSA-N
Gene Information
human ... PPARA(5465)
Application
Fenofibric acid may be used as a reference standard in the determination of fenofibric acid in samples of human plasma using high performance liquid chromatography (HPLC) and liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS).
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
signalword
Warning
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1
Storage Class
11 - Combustible Solids
wgk
WGK 3
hcodes
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC?MS/MS with electrospray ionization: assay development, validation and application to a clinical study.
Trivedi K R, et al.
Journal of Pharmaceutical and Biomedical Analysis, 39(3-4), 661-669 (2005)
Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
Masnatta D L, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications, 687(2), 437-442 (1996)
Roger K Verbeeck et al.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 18(1), 61-67 (2015-04-17)
The therapeutic equivalence of multiple registered fenofibrate formulations, several of which are suprabioavailable and therefore marketed at lower dosage strengths than their reference products, is based on the results of bioequivalence studies. Most of these formulations show a higher bioavailability